Chronic Myeloid Leukemia (CML) is a disease of hematopoietic stem cells which harbor the
chimeric gene Bcr‐Abl. Expression levels of this constitutively active tyrosine kinase are …

Although Imatinib has transformed the treatment of chronic myeloid leukemia (CML), it is not
curative due to the persistence of resistant cells that can regenerate the disease. We have …

The oncoprotein BCR-ABL transforms myeloid progenitor cells and is responsible for the
development of chronic myeloid leukemia (CML). In transformed cells, BCR-ABL suppresses …

Imatinib mesylate (IM), a potent inhibitor of the BCR/ABL tyrosine kinase, has become
standard first-line therapy for patients with chronic myeloid leukemia (CML), but the …

Autophagy is a genetically regulated process of adaptation to metabolic stress and was
recently shown to be involved in the treatment response of chronic myeloid leukemia (CML) …

The introduction of imatinib in the treatment of chronic myeloid leukemia (CML) represents
the most successful example of targeted therapy in human cancer. However, leukemic stem …

Imatinib is a chemotherapeutic drug used for the treatment of chronic myeloid leukemia
(CML). Recent data showed imatinib‐induced cell death in various types of cancers …

Resistance to tyrosine kinase inhibitors (TKIs) remains a limitation to the treatment of chronic
myeloid leukaemia (CML), due in part, to the induction of autophagy. We examined whether …

Previous studies demonstrated that imatinib mesylate (IM) induces autophagy in chronic
myeloid leukemia (CML) and that this process is critical to cell survival upon therapy …

The tyrosine kinase inhibitor imatinib (Gleevec, Novartis Pharmaceuticals Corporation;
Basel, Switzerland) is a powerful drug for treatment of chronic myelogenous leukemia (CML) …